Although androgen withdrawal can control prostate cancer for long periods in many patients, controversy exists regarding management when the tumor becomes androgen independent. Several options are now available.
Methods
A review of the pertinent literature of the last 20 years was conducted to provide guidance in defining and managing hormone-refractory prostate cancer.
Results
Stage D prostate cancer can be subclassified to correlate tumor biology with disease stage. Secondary hormone manipulations may induce responses in patients after failure of initial androgen suppression, and chemotherapy with docetaxel has prolonged survival in patients with androgen-independent prostate cancer (AIPC). The weight of evidence supports the maintenance of castrate levels of testosterone in metastatic AIPC. Bisphosphonates decrease skeletal complications.
Conclusions
Secondary hormone therapy, chemotherapy, and bisphosphonate therapy may provide benefits for selected patients. Correlation of disease stage with biologic characteristics of the tumor and host facilitates proper choices of interventions. Docetaxel-based chemotherapy regimens should be considered for first-line treatment of patients with progressive metastatic AIPC.
References
1.
JemalA., TiwariR.C., MurrayT.Cancer statistics, 2004. CA Cancer J Clin.2004; 54: 8–29.
OhW.K., KantoffP.W.Management of hormone refractory prostate cancer: current standards and future prospects. J Urol.1998; 160: 1220–1229.
4.
HussainM., WolfM., MarshallE.Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol.1994; 12: 1868–1875.
5.
SmaletzO., KelleyW.K., VerbelD.A.A nomogram for overall survival of patients with castrate-metastatic prostate cancer (PC). Proc Annu Meet Am Soc Clin Oncol.2001; 728. Abstract.
6.
SmallE.J., PicusJ., ChenY.A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients: results of CALGB 9583. Proc Annu Meet Am Soc Clin Oncol.2001; 695. Abstract.
TannockI.F., OsobaD., StocklerM.R.Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol.1996; 14: 1756–1764.
9.
GreeneF.L., PageD.L., FlemingI.D., eds. American Joint Committee on Cancer. AJCC Cancer Staging Manual.6th ed.New York, NY: Springer; 2002.
10.
CrawfordE.D., BlumensteinB.A.Proposed substages for metastatic prostate cancer. Urology.1997; 50: 1027–1028.
11.
IsaacsJ.T., CoffeyD.S.Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res.1981; 41: 5070–5075.
DawsonN.A.Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials. J Clin Oncol.1998; 16: 3398–3405.
15.
KantoffP.W., HalabiS., ConawayM.Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol.1999; 17: 2506–2513.
16.
OhW.K.Secondary hormonal therapies in the treatment of prostate cancer. Urology.2002; 60(3 suppl 1): 87–92; discussion 93.
17.
KellyW.K., ScherH.I.Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol.1993; 149: 607–609.
18.
ScherH.I., LiebertzC., KellyW.K.Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol.1997; 15: 2928–2938.
19.
KucukO., FisherE., NoinpourC.M.Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology.2001; 58: 53–58.
20.
JoyceR., FentonM.A., RodeP.High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol.1998; 159: 149–153.
21.
DawsonN.A., ConawayM., HalabiS.A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: Cancer and Leukemia Group B study 9181. Cancer.2000; 88: 825–834.
22.
SandowJ., von RechenbergW., EngelbartK.Pharmacological studies on androgen suppression in therapy of prostate carcinoma. Am J Clin Oncol.1988; 11(suppl 1): S6–S10.
23.
GellerJ., AlbertJ., VikA.Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin Oncol.1988; 15(2 suppl 1): 53–61.
24.
MooreM.J.Quality of life in advanced prostate cancer. Can J Urol.1997; 4(2 suppl 1): 71–73.
25.
NishimuraK., NonomuraN., YasunagaY.Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer.2000; 89: 2570–2576.
26.
KantoffP.W., HalabiS., ConawayM.Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol.1999; 17: 2506–2513.
27.
DawsonN.A.Treatment of progressive metastatic prostate cancer. Oncology (Huntingt).1993; 7: 17–24, 27; discussion 27-29. Published erratum of serious dosage error appears in Oncology (Huntingt). 1993; 7: 2.
28.
SmallE.J., BaronA.D., FippinL.Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol.1997; 157: 1204–1207.
29.
MillikanR., BaezL., BanerjeeT.Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urol Oncol.2001; 6: 111–115.
30.
SmallE.J., PicusJ., ChenY.A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients: results of CALGB 9583. Proc Annu Meet Am Soc Clin Oncol.2001; 695. Abstract.
31.
HarrisK., SmallE.J., FrohlichM.W.Prospective trial of low dose ketoconazole (LDK) therapy in patients (Pts) with androgen independent prostate cancer (AIPC). Proc Annu Meet Am Soc Clin Oncol.2001; 20: 2419.
32.
RobertsonC.N., RobersonK.M., PadillaG.M.Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst.1996; 88: 908–917.
33.
ShahidiM., NormanA.R., GaddJ.Prospective review of diethylstilbestrol in advanced prostate cancer no longer responding to androgen suppression. Proc Annu Meet Am Soc Clin Oncol.2001; 2455. Abstract.
34.
SmithD.C., RedmanB.G., FlahertyL.E.A phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer. Urology.1998; 52: 257–260.
35.
RosenbaumE., WygodaM., GipsM.Diethylstilbestrol is an active agent in prostatic cancer patients after failure to complete androgen blockade. Proc Annu Meet Am Soc Clin Oncol.2000; 349. Abstract.
36.
OhW.K., GeorgeD.J., HackmannK.Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology.2001; 57: 122–126.
37.
PfeiferB.L., PiraniJ.F., HamannS.R.PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int.2000; 85: 481–485.
38.
KubotaT., HisatakeJ., HisatakeY.PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo. Prostate.2000; 42: 163–171.
39.
DiPaolaR.S., ZhangH., LambertG.H.Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med.1998; 339: 785–791.
40.
AdesT., GanslerT., MillerM.PC-SPES: current evidence and remaining questions. CA Cancer J Clin.2001; 51: 199–204.
41.
OhW.K., KantoffP.W., WeinbergV.Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol.2004; 22: 3705–3712.
42.
SharifiR., SolowayM.Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer: the Leuprolide Study Group. J Urol.1990; 143: 68–71.
43.
FowlerJ.E.Jr, WhitmoreW.F.Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol.1981; 126: 372–375.
44.
TaylorC.D., ElsonP., TrumpD.L.Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol.1993; 11: 2167–2172.
45.
KellyW.K., ScherH.I., MazumdarM.Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol.1993; 11: 607–615.
46.
BubleyG.J., CarducciM., DahutW.Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol.1999; 17: 3461–3467.
47.
RaghavanD., CoxK., PearsonB.S.Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol.1993; 72: 625–628.
48.
von RoemelingR., FisherH.A.G., HortonJ.Daily oral cyclophosphamide is effective in hormone refractory prostate cancer: a phase I/II pilot study. Proc Annu Meet Am Soc Clin Oncol.1992; 213. Abstract.
49.
UkimuraO., KamoiK., HongoF.Oral administration of dexamethasone in combination with UFT and cyclophosphamide for the treatment of hormone-refractory prostate cancer. Proc Annu Meet Am Soc Clin Oncol.2001; 2412. Abstract.
50.
Maulard-DurduxC., DufourB., HennequinC.Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer.1996; 77: 1144–1148.
51.
WozniakA.J., BlumensteinB.A., CrawfordE.D.Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer: a Southwest Oncology Group study. Cancer.1993; 71: 3975–3978.
52.
VarkarakisM.J., KirdaniR.Y., MurphyG.P.Antiprostatic effects of a nitrogen mustard of estriol. Proc Soc Exp Biol Med.1975; 148: 904–908.
53.
Hartley-AspB., KruseE.Nuclear protein matrix as a target for estramustine-induced cell death. Prostate.1986; 9: 387–395.
54.
PientaK.J., LehrJ.E.Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol.1993; 149: 1622–1625.
55.
AttivissimoL.A., FettenJ.V., KreisW.Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer. Am J Clin Oncol.1996; 19: 581–583.
56.
HudesG.R., GreenbergR., KrigelR.L.Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol.1992; 10: 1754–1761.
57.
PetrylakD.P., MacarthurR.B., O'ConnorJ.Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol.1999; 17: 958–967.
58.
HudesG.R., NathanF.E., KhaterC.Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol.1995; 22(5 suppl 12): 41–45.
59.
MareelM.M., StormeG.A., DragonettiD.M.Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro. Cancer Res.1988; 48: 1842–1849.
60.
PientaK.J., RedmanB., HussainM.Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol.1994; 12: 2005–2012.
61.
HudesG.R., NathanF., KhaterC.Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol.1997; 15: 3156–3163.
62.
TierstenA.D., NelsonC., TalbotS.A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer.2003; 97: 537–544.
63.
OudardS., CatyA., HumbletY.Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann Oncol.2001; 12: 847–852.
64.
HudesG., EinhornL., RossE.Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol.1999; 17: 3160–3166.
65.
HudesG., EinhornL., RossE.Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. Classic Papers and Current Comments.2001; 6: 318–325.
66.
HorwitzS.B.Taxol (paclitaxel): mechanisms of action. Ann Oncol.1994; 5(suppl 6): S3–S6.
67.
RingelI., HorwitzS.B.Studies with RP 56976 (taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst.1991; 83: 288–291.
68.
DiazJ.F., AndreuJ.M.Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry.1993; 32: 2747–2755.
69.
BerryW., DakhilS., GregurichM.A.Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol.2001; 28: 8–15.
70.
Sitka CopurM., LedakisP., LynchJ.Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol.2001; 28(4 suppl 15): 16–21.
71.
UrakamiS., IgawaM., KikunoN.Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol.2002; 168: 2444–2450.
72.
SmithD.C., EsperP., StrawdermanM.Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol.1999; 17: 1664–1671.
73.
SavareseD.M., HalabiS., HarsV.Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol.2001; 19: 2509–2616.
74.
KellyW.K., CurleyT., SlovinS.Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol.2001; 19: 44–53.
75.
BeerT.M., EilersK.M., GarzottoM.Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol.2003; 21: 123–128.
76.
TannockI.F., deWitR., BerryW.J.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med.2004; 351: 1502–1512.
77.
PetrylakD.P., TangenC.M., HussainM.H.Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med.2004; 351: 1513–1520.
78.
FiggW.D., ArlenP., GulleyJ.A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol.2001; 28(4 suppl 15): 62–66.
79.
BeerT.M., HoughK.M., GarzottoM.Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol.2001; 28(4 suppl 15): 49–55.
80.
HershbergerP.A., YuW.D., ModzelewskiR.A.Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res.2001; 7: 1043–1051.
81.
TherasseP., ArbuckS.G., EisenhauerE.A.New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst.2000; 92: 205–216.
82.
NelsonJ.B., HedicanS.P., GeorgeD.J.Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med.1995; 1: 944–949.
83.
NelsonJ., BagnatoA., BattistineB.The endothelin axis: emerging role in cancer. Nature.2003; 3: 110–116.
GohjiK., KitazawaS., TamadaH.Expression of endothelin receptor a associated with prostate cancer progression. J Urol.2001; 165: 1033–1036.
86.
OpgenorthT.J., AdlerA.L., CalzadillaS.V.Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther.1996; 276: 473–481.
87.
CarducciM.A., PadleyR.J., BrailJ.Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol.2003; 21: 679–689.
88.
DiamondT., CampbellJ., BryantC.The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer.1998; 83: 1561–1566.
89.
SmithM.R., EasthamJ., GleasonD.M.Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol.2003; 169: 2008–2012.
90.
SmithM.R., McGovernJ.P., ZietmanA.L.Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med.2001; 345: 948–955.
91.
HortobagyiG.N., TheriaultR.L., PorterL.Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med.1996; 335: 1785–1791.
92.
TheriaultR.L., LiptonA., HortobagyiG.N.Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol.1999; 17: 846–854.
93.
PavlakisN., StocklerM.Bisphosphonates for breast cancer. Cochrane Database Syst Rev.2002. CD003474.
